Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063855 · ClinicalTrials.gov registry record · Phase 3
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 495
- Enrollment target
NCT01063855 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 495 participants.
The verdict
NCT01063855, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 495 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor (ie, sildenafil, vardenafil, or tadalafil) for erectile dysfunction.
Interventions
- DRUG Placebo
- DRUG Dapoxetine
- DRUG PDE5I (phosphodiesterase-5 inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063855
The ClinicalTrials.gov registry entry for NCT01063855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01063855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063855 about?
NCT01063855 is a clinical study titled "Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction". The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor (ie, sildenafil, vardenafil, or tadalafil) for erectile dysfunction.
What is the current status of trial NCT01063855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 495 participants. The study started on 2010-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01063855?
The interventions under investigation include: Placebo (DRUG), Dapoxetine (DRUG), PDE5I (phosphodiesterase-5 inhibitor) (DRUG).
Who is sponsoring clinical trial NCT01063855?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.